Allergy Therapeutics plc (LON:AGY – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 6 and last traded at GBX 6.38, with a volume of 398951 shares trading hands. The stock had previously closed at GBX 6.82.
Allergy Therapeutics Price Performance
The business’s fifty day moving average price is GBX 8.55 and its 200-day moving average price is GBX 10.15. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The company has a market capitalization of £424.28 million, a P/E ratio of -6.91, a P/E/G ratio of -30.70 and a beta of 0.87.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
